Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029

1.1 List of Tables
1.2 List of Figures

2.1 The Acute Myeloid Leukemia Market Size Will Grow at a 13.6% Rate During 2019-2029
2.2 Recent Approvals and Novel Agents Drive Competition in the First-Line Induction Setting but the Relapsed/Refractory Market Remains Underserved
2.2.1 Key Drug Developers in Acute Myeloid Leukemia
2.3 Poor Long-Term Survival Remains an Unmet Need and Provides Opportunity for New Market Entrants
2.4 Increased Adoption of Targeted Therapies and Introduction of Immunotherapies Poised to Change the Treatment Paradigm
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used and Not Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for AML (2019-2029)
5.5.1 Diagnosed Incident Cases of AML
5.5.2 Age-Specific Diagnosed Incident Cases of AML
5.5.3 Sex-Specific Diagnosed Incident Cases of AML
5.5.4 Diagnosed Incident Cases of AML by Risk Group
5.5.5 Diagnosed Incident Cases of Secondary AML
5.5.6 Diagnosed Incident Cases of APL
5.5.7 Five-Year Diagnosed Prevalent Cases of AML
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Coronavirus Disease 2019 (COVID-19) Impact
5.6.3 Limitations of Analysis
5.6.4 Strengths of Analysis

6.1 Overview

7.1 Overview
7.2 Outcomes in Secondary AML
7.3 Translating Complete Response to Durable, Five-Year Survival
7.4 Treatments in the Second Line and Beyond
7.5 Improved Options for Older Patients
7.6 Improved Outcomes after Transplant

8.1 Overview
8.1.1 Improved Cytotoxic Agents
8.1.2 Exploiting AML Vulnerabilities
8.1.3 Next-Generation Targeted Therapies
8.1.4 Revisiting Immunotherapies
8.2 Clinical Trials Design
8.2.1 Important Trials
8.2.2 Primary and Secondary Endpoints
8.2.3 Comparison Arm
8.2.4 Choice of Patients
8.2.5 Future Trends

9.1 Overview
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development

10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
10.4.4 China
11 Appendix

Table 1: Acute Myeloid Leukemia: Key Metrics in the 8MM
Table 2: Clinically Relevant Segmentation of AML Patients
Table 3: Risk Factors for AML
Table 4: Treatment Guidelines for Acute Myeloid Leukemia
Table 5: Leading Treatments for Acute Myeloid Leukemia, 2020
Table 6: Comparison of Therapeutic Classes in Development for Acute Myeloid Leukemia, 2019-2029
Table 7: Innovative Early-Stage Approaches for Acute Myeloid Leukemia, 2020
Table 8: Drugs in Development (US/Global) for Acute Myeloid Leukemia, 2020
Table 9: Clinical Benchmarking of Key Pipeline Products (Intensive Induction Regimens)
Table 10: Clinical Benchmarking of Key Pipeline Products (Lower-intensity regimens)
Table 11: Clinical Benchmarking of Key Pipeline Products (Relapsed/Refractory Regimens)
Table 12: Commercial Benchmarking of Key Pipeline Products (Intensive Induction Regimens)
Table 13: Commercial Benchmarking of Key Pipeline Products (Lower-intensity regimens)
Table 14: Commercial Benchmark of Key Pipeline Products (Relapsed/Refractory Regimens)
Table 15: Key Events Impacting Sales for Acute Myeloid Leukemia in the US, 2019-2029
Table 16: Acute Myeloid Leukemia Market - Global Drivers and Barriers, 2019-2029
Table 17: Key Historical and Projected Launch Dates for Acute Myeloid Leukemia
Table 18: Key Historical and Projected Patent Expiry Dates for Acute Myeloid Leukemia
Table 19: US Annual Cost of Therapy for the Most Common Chemotherapies in Acute Myeloid Leukemia
Table 20: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for Acute Myeloid Leukemia in 2019 and 2029
Figure 2: Competitive Assessment of Key Pipeline Intensive Induction Regimens Benchmarked Against the SOC, 7+3
Figure 3: Competitive Assessment of Key Pipeline Low-Intensity Regimens Benchmarked Against the SOC, Venclexta + Low-Intensity Regimen
Figure 4: Competitive Assessment of Key Pipeline Relapse/Refractory Regimens Benchmarked Against the SOC, FLAG-IDA
Figure 5: Comparison of Normal and Leukemia Blood Cell Differentiation
Figure 6: 8MM, Diagnosed Incidence of AML, Men and Women, Ages 18 Years and Older, 2009-2019
Figure 7: Sources Used to Forecast the Diagnosed Incident Cases of AML
Figure 8: Sources Used to Forecast the Diagnosed Incident Cases of AML by Risk Group
Figure 9: Sources Used to Forecast the Diagnosed Incident Cases of Secondary AML
Figure 10: Sources Used to Forecast the Diagnosed Incident Cases of APL
Figure 11: Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of AML
Figure 12: 8MM, Diagnosed Incident Cases of AML, Men and Women, Ages =18 Years, 2019
Figure 13: 8MM, Diagnosed Incident Cases of AML by Age Group, Men and Women, 2019
Figure 14: 8MM, Diagnosed Incident Cases of AML by Sex, Ages =18 Years, 2019
Figure 15: 8MM, Diagnosed Incident Cases of AML by Risk Group, Men and Women, Ages =18 Years, 2019
Figure 16: 8MM, Diagnosed Incident Cases of Secondary AML, Men and Women, Ages =18 Years, 2019
Figure 17: Diagnosed Incident Cases of APL, 8MM, Men and Women, Ages =18 Years, 2019 and 2029
Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of AML, Men and Women, Ages =18 Years, 2019
Figure 19: Current Treatment Algorithm of Acute Myeloid Leukemia
Figure 20: Unmet Needs and Opportunities in Acute Myeloid Leukemia
Figure 21: Overview of the Development Pipeline in Acute Myeloid Leukemia
Figure 22: Key Phase II and III Trials for Promising Injectable Pipeline Agents
Figure 23: Key Phase II and III Trials for Promising Oral Pipeline Agents
Figure 24: Competitive Assessment of Key Pipeline Intensive Induction Regimens Benchmarked Against the SOC, 7+3
Figure 25: Competitive Assessment of Key Pipeline Low-Intensity Regimens Benchmarked Against the SOC, Venclexta + Low-Intensity Regimen
Figure 26: Competitive Assessment of Key Pipeline Relapsed/Refractory Regimens Benchmarked Against the SOC, FLAG-IDA
Figure 27: Global (8MM) Sales Forecast by Country for Acute Myeloid Leukemia in 2019 and 2029
Figure 28: Global Sales Forecast by Class for Acute Myeloid Leukemia in 2019 and 2029
Figure 29: Sales Forecast by Class for Acute Myeloid Leukemia in the US in 2019 and 2029
Figure 30: Sales Forecast by Class for Acute Myeloid Leukemia in the 5EU in 2019 and 2029
Figure 31: Sales Forecast by Class for Acute Myeloid Leukemia in Japan in 2019 and 2029
Figure 32: Sales Forecast by Class for Acute Myeloid Leukemia in China in 2019 and 2029